NCT01182155|CompletedDMC
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · Stanford University
observational
20
1 country
1
Study Start
August 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2011
Actual (reported)Study Completion
March 2012
Actual (reported)Patients treated with radiation therapy for lung tumors can experience inflammation after treatment. This study hopes to evaluate the use of breath analysis to evaluate changes in the composition of exhaled breath in patients undergoing radiotherapy. If changes can be detected, this may ultimately serve as biomarkers for identifying patients at highest risk for radiation-induced lung injury (radiation pneumonitis).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2010
Date type not reportedThis date has not been verified as actual or estimated.
August 12, 2010
Actual (reported)August 16, 2010
Actual (reported)September 2011
Actual (reported)March 2012
Actual (reported)Pre and post-radiation FeNO (fraction of exhaled nitric oxide) measurements
Every 3 months for 1 year
Pre and post-radiation CO (carbon monoxide), CO2 (carbon dioxide), and N2O (nitrous oxide) measurements and feasibility as the fraction of patients unable to give a breath sample. Adverse events are not expected but any that appear related to the breath
1 yr
Standard of care
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with lung tumors who are undergoing radiation therapy
Stanford University School of Medicine
Stanford, California, 94305, United States
Dr. Maximilian Diehn MD/PhD
Stanford University
20 participants (actual enrollment reported by the registry).
First Submitted
August 12, 2010
First Posted
August 16, 2010
Study Start
August 2010
Date type not reportedThis date has not been verified as actual or estimated.
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
Contact the study team to confirm eligibility.
Primary Completion
September 2011
Actual (reported)Study Completion
March 2012
Actual (reported)Last Updated
July 1, 2016
Record last verified: 2016-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: